Executive Medical Consultant

Prof. Eitan Kerem

פרופ איתן כרם, צילום אבי חיון 2

Eitan Kerem, MD, was until recently the Head of the Pediatric Division and the Pediatric Pulmonology Unit of the Hadassah Medical Center in Jerusalem, Israel. He graduated from the Hebrew University–Hadassah Medical School in Jerusalem, and completed pediatric residency, and did 3-year fellowship in pediatric respiratory diseases at the Hospital for Sick Children in Toronto, ON, Canada. He built the Pulmonary and Cystic Fibrosis Clinic of the Shaare Zedek Medical Center in Jerusalem, and subsequently he was elected Head of the Department of Pediatrics at the Hadassah Medical Center, and Professor in Pediatrics at the Hebrew University–Hadassah Medical School in 2002. In 2011 he was appointed as Chairman of Pediatrics at the Hadassah University Medical Center. 

Professor Kerem’s interest in cystic fibrosis (CF) spans all aspects of the condition. He was involved in formulating the guidelines that paved the road to the standardization of CF care in Europe and other parts of the world. His main research was in understanding the relationship between genotype and phenotype in CF, factors that influenced clinical outcome and prevention of complications. In addition, his research interests included asthma and community-acquired pneumonia. He has been a principal investigator in many national and international multicenter clinical trials in CF and is an author of key publications in this field.

Professor Kerem was Chairman of the Medical Advisory Board for the Israeli CF Foundation and served as a board member of the European Cystic Fibrosis Society (ECFS), initiating the development of the ECFS Patient Registry. He has been a member of numerous organizing committees for national and international conferences, and was a president of the International Congress on Pediatric Pulmonology. He has received many awards, including the Ordine Della Stella Della Solidarietà Italiana Award; the Shalem Award bestowed by the Israeli National Foundation for the development of services for individuals with intellectual disabilities; and the ECFS Award acknowledging his substantial and remarkable contribution to CF research. In 2016 he received an Honorary Fellowship of the Royal College of Paediatrics and Child Health, UK. Prof. Kerem was a member of the advisory board in pharma companies developing new treatment for CF.

Scroll Up Skip to content